Cingulate therapeutics ipo
WebCingulate Therapeutics, LLC (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s disruptive, proprietary Precision Timed Release™ (PTR™) drug delivery platform technology incorporating a proprietary Erosion Barrier Layer (EBL) enabling the creation of true once … WebOct 4, 2024 · The IPOs of neuroscience biotech Cingulate and Cognition Therapeutics, ... Shares of Verve Therapeutics — the year's 10th biotech IPO by size — are up more …
Cingulate therapeutics ipo
Did you know?
WebMorristown, New Jersey. Craig S. Gilgallon is a Co-Founder of Cingulate Therapeutics and serves as General Counsel, Chief Legal Officer and … Web1y Target Est. 5.88. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return ...
WebCingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate … WebDec 8, 2024 · Cingulate Inc. (NASDAQ: CIN), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline ...
WebApr 10, 2024 · Market Average Movement. 6.4%. 10% most volatile stocks in US Market. 16.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: CING is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week. Volatility Over Time: CING's weekly volatility has increased from 16% to 22% over the … WebMar 14, 2024 · With sales of ADHD medication increasing 8 percent each year since 2010, Cingulate could be in a position to capture a significant share of the $18 billion total ADHD prescription drug market.
WebPipeline Cingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $22.1 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is …
WebOct 13, 2024 · Comments by IPO Boutique, including our e-mail alerts and advisories are the observations of the staff of IPO Boutique. They are not intended to be absolute recommendations to buy, hold or sell securities but carefully chosen advisory information, or an endorsement of any specific security or trading strategy. daryl and john musiciansWebDec 9, 2024 · That price was the low end of an already revised range of $6 to $8. Cingulate had originally planned to offer 4.5 million shares at a $10 to $12 range, then lowered the … bitcoin cash good investmentWebOct 13, 2024 · Cingulate Therapeutics' IPO date and price. Cingulate is expected to start trading on Oct. 15. The company now plans to raise $40 million by offering 4.4 million … bitcoin cash gas feeWebSep 16, 2024 · Cingulate Therapeutics IPO - Photo: Shutterstock. Cingulate Therapeutics threw its hat into the ring of biopharmaceutical companies that have … bitcoin cash grafikWebOct 8, 2024 · Cognition Therapeutics priced its IPO at the mid-point. Cognition Therapeutics raised $45.2 million by offering 3.8 million shares in the IPO at $12 each. Previously, the company planned to offer ... bitcoin cash hashWebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% … daryl and lisa tillman real estateWebAbout Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery … bitcoin cash hashrate chart